Press release
Hypertension drugs Market is expected to reach USD 33.1 billion by 2024 | Key players are Pfizer Inc., Novartis AG, Johnson & Johnson Ltd., Sanofi S.A, Ranbaxy Laboratories Limited, AstraZeneca Plc. and Lupin Limited
Human health is affected by a variety of factors, including rapid urbanization, ageing of the population and the globalization of unhealthy lifestyles. Hypertension is one of the key health problems seen in developed and developing countries. It is a silent and invisible killer that rarely causes symptoms and is one of the main risk factors for heart disease and ischemic and hemorrhagic stroke. Hypertension can also lead to a variety of other conditions including kidney failure, visual impairment, heart failure and retinal haemorrhage. According to the World Health Organization (WHO), 7.5 million deaths are due to hypertension worldwide and account for 12.8% of all deaths. In general, in 2008, the prevalence of hypertension was around 40% in adults of 25 years.
Hypertension Drugs Market size is set to reach USD 33.1 billion by 2024, at a CAGR of 1.12% during 2016 to 2024.
Get Sample of the report @ https://www.researchcosmos.com/request/global-hypertension-drugs-market-analysis-and-forecast-2016/9684887
Drivers and Restraints:
Changes in lifestyle, high levels of stress and population increases, early detection and combined dose penetration would be the main drivers of growth in the antihypertensive market. Patent expiration of important drugs such as Cozaar (Merck), Diovan (Novartis), Exforge (Novartis), Revatio (Pfizer), Avapro (Sanofi Aventis), Atacand (AstraZeneca), BIopress (Benalar), a low diagnostic rate and the increased penetration of generics would slow down the antihypertensive market, but the new hypertension drugs under development could recover the losses associated with patent expiration.
Geographical Insights:
Based on geography, the hypertension drugs market can be segmented in North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. The global hypertension drugs market is dominated by North America and Europe. According to the world health organization, the prevalence of hypertension is highest in Africa and the lowest in America region. In Africa, more than 40% of adults have high blood pressure and many of them are not diagnosed due to the high cost of medications. A greater generalization of local businesses can be a challenge for the market. Similarly, in recent years, there has been a significant improvement in the treatment of hypertension, which contributes to a sharp decline in mortality rates in North America and Western Europe.
Browse More Details of the report and TOC @ https://www.researchcosmos.com/reports/global-hypertension-drugs-market-analysis-and-forecast-2016-2024-industry-growth-opportunities/9684887
Key Players of Hypertension Drugs Market
Pfizer Inc., Novartis AG, Johnson & Johnson Ltd., Sanofi S.A, Merck & Co., Daiichi - Sankyo, Ranbaxy Laboratories Limited AstraZeneca Plc. and Lupin Limited are the major players in the global hypertension drugs market.
Scope of the report:
The report offers a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the market dynamics and trends are discussed in detail at the product level. Further, the performance of the market at the regional and country-level is assessed and the prospects with high growth potential are identified and debated.
The key players in the industry are profiled providing insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategical activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided.
The report also offers a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.
What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.
Make an Inquiry before buying @ https://www.researchcosmos.com/inquire/global-hypertension-drugs-market-analysis-and-forecast-2016/9684887
Research Cosmos is a provider of standard and customized Industry research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending Industry reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.
Kevin Stewart
kevin@researchcosmos.com
Global Sales Manager
Research Cosmos
www.researchcosmos.com
+1 888 709 8757
LinkedIn - https://www.linkedin.com/company/market-research-cosmos
Twitter - https://twitter.com/researchcosmos
Google+ - https://plus.google.com/109756852849129986268
Facebook - https://www.facebook.com/researchcosmos/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertension drugs Market is expected to reach USD 33.1 billion by 2024 | Key players are Pfizer Inc., Novartis AG, Johnson & Johnson Ltd., Sanofi S.A, Ranbaxy Laboratories Limited, AstraZeneca Plc. and Lupin Limited here
News-ID: 1266134 • Views: …
More Releases from Research Cosmos
Mobile Phone Insurance Market Size to Reach USD 32.24 Bn By 2025
The size of the Global mobile phone insurance market is estimated to reach USD 32.24 billion by 2025, growing at a CAGR of 12.5%, as per the recently published report by Research Cosmos. It is worth to claim insurance for mobile phones as we are spending a lot of money on purchasing. The policies include accidental damage, water damage, and screen cracking.
Browse details of the report @ https://www.researchcosmos.com/reports/mobile-phone-insurance-market/199557834
Growing utilization…
Social Employee Recognition Systems Market Predicted to grow at a CAGR of xx By …
Social Employee Recognition Systems Market Analysis Size, Growth rate and Overview:
Social Employee Recognition Systems Market was valued at USD xx million in 2018 and is expected to reach almost USD xx million by the end of 2025, growing at a CAGR of around xx% over the predicted period.
Throughout the world, social employee recognition systems have expanded dramatically to address the need to move away from traditional methods and programs of…
More Releases for Hypertension
Hypertension Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hypertension Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hypertension Pipeline Report
• DelveInsight's Hypertension…
Hypertension Drugs Market - Breaking the Pressure: Hypertension Drugs Redefining …
Newark, New Castle, USA: The "Hypertension Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypertension Drugs Market: https://www.growthplusreports.com/report/hypertension-drugs-market/8760
This latest report researches the industry structure, sales, revenue,…
Hypertension Management Devices Market: Rise in Prevalence of Resistant Hyperten …
Market Analysis and Insights of Hypertension Management Devices Market
Hypertension Management Devices Market to account USD 9.50 billion and growing at a CAGR of 7.27% by 2032. Although there are still numerous variations available, the major market players are currently developing and testing clinical versions of hypertension treatment devices. Due to the lack of available effective medications, these medical devices are being created with the primary goal of managing cardiovascular illnesses…
Anti-hypertension - Drug Pipeline Landscape, 2022
Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
Renal Hypertension: Diagnosis & Treatment
“Hypertension & Cardiovascular disease after Kidney Transplantation” is one of the workshops to be conducted by Dr. Hossein Tabriziani of Loma Linda University, USA under the session ‘Renal Hypertension’ at the meeting 2nd International Conference on Hypertension & Healthcare which is going to be held at Amsterdam, Netherlands during September 11-13, 2017.
High blood pressure is a leading cause of kidney disease and kidney failure ESRD (end stage renal disease). Hypertension…
